‘Immediately Practice-Changing’ Trial in Small Cell Lung Cancer

By News Health
2 days Ago

(MedPage Today) — CHICAGO — The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial showed.
In patients whose…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115891

Author :

Publish date : 2025-06-03 21:16:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

A Town's Worth of Endoscopy Waste; IBS Drug Toxicity; E. Coli-Tainted Ground Beef

Ranibizumab Ocular Implant Shows Long-Term Benefits in Retinal Disease

Setting Up a Successful Fracture Liaison Service

A Double Threat to Allergy Patients

Primary Surgery for Ovarian Cancer Scores a Win -- Sort Of

Fusion power may never happen if we don't fix the lithium bottleneck